167,976 Shares in Pfizer Inc. (NYSE:PFE) Bought by Allstate Corp

Allstate Corp acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 167,976 shares of the biopharmaceutical company's stock, valued at approximately $4,456,000.

Several other institutional investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 0.3 %

Shares of PFE stock traded up $0.09 during mid-day trading on Monday, hitting $25.30. The stock had a trading volume of 28,456,940 shares, compared to its average volume of 44,871,637. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm's 50-day moving average is $26.06 and its two-hundred day moving average is $26.90. The firm has a market capitalization of $143.48 billion, a P/E ratio of 17.93, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Bank of America reaffirmed a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.